VivoSeq
Oncology

Central Nervous System Lymphoma

71

Pipeline Programs↗

29

Active Trials↗

41

Companies Involved↗

Central Nervous System Lymphoma is a moderately active landscape with 71 programs across 41 companies. The most active players are AstraZeneca, Genmab, PersonGen BioTherapeutics (Suzhou) Co., Ltd.. 3 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

67/100

Pipeline Velocity

22/100

Mech. Concentration

8/100

Completion Rate

71/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

2 programs

Phase 1Genmab logo

Genmab

1 program

Phase 1P

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

1 program

Phase 1Akero Therapeutics logo

Akero Therapeutics

1 program

Phase 1Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group

3 programs

Phase 2E

Eastern Cooperative Oncology Group

3 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Small molecule

60 of 80 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody1215%Protein / enzyme45%Cell therapy34%Antibody–drug conjugate11%

Small molecule leads; the ring shows all 80 classified programs, each share of the total. Modality classified for 100% of 84 pipeline programs.

Analysis

Trial Status

75

clinical trials

Recruiting21 · 28%
Completed20 · 27%
Unknown status18 · 24%
Active, not recruiting5 · 7%
Terminated4 · 5%
Withdrawn4 · 5%
Other3 · 4%

Clinical Trials

Trial Activity

75 trials

Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma
Recruiting·—·Phase 1·NCT05625594·20 enrolled
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
Recruiting·PProvidence Health & Services·Phase 2·NCT06175000·28 enrolled
Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT05600660·28 enrolled
Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma
Recruiting·SSeoul National University Bundang Hospital·Phase 2·NCT05260619·28 enrolled
The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT05931328·28 enrolled
Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma
Recruiting·—·N/A·NCT06946407·41 enrolled
Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)
Recruiting·—·Phase 2·NCT05549284·36 enrolled
Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT04961515·19 enrolled
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT07137494·12 enrolled
Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study
Recruiting·SSecond Affiliated Hospital of Soochow University·Phase 2·NCT07002099·26 enrolled
Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma
Recruiting·HHenan Cancer Hospital·Phase 2·NCT05209620·30 enrolled
Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
Recruiting·ZZhejiang Cancer Hospital·Phase 2·NCT07416890·24 enrolled
High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma
Recruiting·SSichuan University·Phase 2·NCT07014943·34 enrolled
Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Recruiting·—·Phase 2·NCT04070040·21 enrolled
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Recruiting·CCuris, Inc.·Phase 1/2·NCT03328078·152 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)